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Abstract 
Aims/Hypothesis  In vitro studies point to a toxic effect of high glucose and non-esterified 
fatty acids on beta-cells. Whether elevated levels of glucose and lipids induce beta-cell loss in 
vivo is less clear. The domestic cat has recently been proposed as a valuable animal model for 
human type 2 diabetes, since feline diabetes shows several similarities including obesity-
induced insulin resistance, impaired beta-cell function, decreased number of beta-cells and 
pancreatic amyloid deposition. 
Methods  We infused healthy cats with glucose or lipids for 10 days to clamp their blood 
concentrations at the approximate level found in untreated feline diabetes (glucose: 25-30 
mmol/l; triacylglycerols: 3-7 mmol/l). 
Results  Glucose and lipid levels were adequately targeted. Plasma non-esterified fatty acids 
were increased by lipid infusion 1.7-fold. A dramatic and progressive decline of plasma 
insulin levels was observed in glucose-infused cats beginning after 2 days of hyperglycaemic 
clamp. In contrast, plasma insulin concentration and glucose tolerance test were not affected 
by hyperlipidaemia. Compared to controls, glucose-infused cats had a 50% decrease in beta-
cells per pancreatic area. Apoptotic islet cells and cleaved caspase-3-positive beta-cells were 
observed in glucose-infused cats only. 
Conclusions/interpretation  Sustained hyperglycaemia but not hyperlipidaemia induces early 
and severe beta-cell dysfunction in cats, and excess glucose causes beta-cell loss via apoptosis 
in vivo. Hyperglycaemic clamps in cats may represent a good model to study the pathogenesis 
of glucose toxicity in the beta-cells. 
 
Keywords: feline, diabetes, glucose toxicity, apoptosis, hyperglycaemia, hyperlipidaemia 
Abbreviations: FLIP, FLICE/caspase-8-inhibitory protein; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; H&E, hematoxylin and eosin; ivGTT, intravenous glucose 
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tolerance test; MCP-1, monocyte chemoattractant protein-1; PAS, periodic acid-schiff; 
PCNA, proliferating nuclear antigen. 
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Introduction 
Based on results obtained in cultured rodent and human islet cells, it is assumed that poorly 
controlled hyperglycaemia and hyperlipidaemia in diabetic patients negatively affect beta-
cells, leading to a vicious cycle of progressive deterioration of beta-cell function and 
ultimately beta-cell loss [1]. The detrimental effects of sustained high glucose and lipid levels 
on insulin secretion and beta-cell viability are referred to as “glucotoxicity” and 
“lipotoxicity”[2,3]. 
In vitro studies demonstrated that human beta-cells exposed to high glucose levels have a 
marked increase in the rate of apoptosis [4,5]. Recently, however, the role of excess glucose 
on beta-cell apoptosis in human diabetes in vivo was questioned based on a post-mortem 
study [6]. In that study, humans with recent-onset type 1 diabetes had only a modest degree of 
apoptosis in the remaining beta-cells, despite prevailing hyperglycaemia in most individuals 
[6]. Similar to the in vitro effects of high glucose levels, NEFA seem to be harmful to beta-
cells when present at high concentrations. High levels of saturated NEFA, in particular 
palmitate, induce apoptosis that is independent from glucose levels in cultured human and rat 
islets [7,8]. 
Several groups used a variety of glucose and lipid infusion protocols to investigate the direct 
effects of hyperglycaemia and hyperlipidaemia on the beta-cells in vivo [9-19]. In previous 
studies in rodents, glucose and lipid solutions were administered at a constant rate and for no 
longer than 2-4 days. Protocols with constant rate infusion, however, do not allow to maintain 
a specific level of hyperglycaemia or hyperlipidaemia. Indeed, in most studies 
hyperglycaemia and hyperlipidaemia have been short-lasting or of mild degree, and beta-cell 
dysfunction and loss was not consistently shown. Thus, to investigate the mechanisms of 
gluco- and lipotoxicity in vivo, infusion protocols should be modified to allow sustained and 
long-term hyperglycaemia or hyperlipidaemia at specific levels. Targeting blood glucose and 
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lipids levels at a predefined range can be achieved by frequently adjusting the rate of infusion. 
Based on our experience with pet animals, domestic cats can be amenable to such chronic 
infusion studies. 
The present study was therefore conducted to test whether sustained high glucose or lipid 
levels lead to beta-cell dysfunction and beta-cell loss in vivo. Cats are an interesting model of 
diabetes because they spontaneously develop a form of the diseases that is very similar to 
human type 2 diabetes [20-22]. Diabetic cats are often middle aged, a genetic predisposition is 
described, obesity leading to insulin resistance is a major risk factor, and impaired beta-cell 
function is present. The most striking histological similarity between human type 2 diabetes 
and the disease in cats is amylin-derived islet amyloidosis that is found in more than 80% of 
diabetic felines. Most diabetic cats have beta-cell loss of at least 50% [22-26]. Here, cats were 
infused for 10 days with glucose or lipids to clamp their blood concentrations at the 
approximate level found in untreated feline diabetes (glucose: 25-30 mmol/l; triacylglycerols: 
3-7 mmol/l)[27,28]. 
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Research Design and Methods 
Animals and infusions 
Twenty-two neutered-male, 15-18 months old, healthy domestic-shorthair cats (Charles River, 
L'arbresle, France) were used following principles of laboratory animal care (Veterinary 
Office of Zuerich, Switzerland, permission nr. 51/2007). 
Cats were randomly divided into 4 groups. Groups I, II and III were infused over 10 days 
through a jugular catheter. Group I (6 cats) received 50% glucose added to saline. Blood 
glucose was evaluated 6-12 times per day and the infusion rate was adjusted to target levels at 
25-30 mmol/l. Group II (6 cats) received lipids (Lipovenoes 10%, Fresenius-Kabi, Bad 
Homburg, Germany). The lipid composition is provided in Electronic supplementary material 
(ESM) Table 1. Blood triacylglycerols were measured 2-3 times per day to target levels at 3-7 
mmol/l. Group III (5 cats) served as control and was infused with saline. During the 10-day 
infusion period, cats were singly-housed in a cage. The remaining 5 cats (Group IV) were 
used as additional controls. These cats were not infused and were group-housed during the 
study. They served to investigate the potential confounding effect of experiment-induced 
stress on glucose and lipid metabolism. 
 
Biochemical measurements 
In plasma glucose was measured by a colorimetric hexokinase/glucose-6-phosphate 
dehydrogenase method and triacylglycerols by a colorimetric assay using glycerophosphate 
oxidase coupled to phenol and 4-aminophenazone (Roche, Vienna, Austria). Serum sodium 
and potassium were analyzed with the ion-selective electrode method (Roche). Serum NEFA 
were measured with the NEFA-C kit (Wako, Richmond, PA, USA) and plasma β-
hydroxybutyrate with the 3-hydroxybutyrate dehydrogenase method (Randox, Crumlin, UK). 
For measurement of feline plasma insulin we validated a cross-reacting porcine insulin 
radioimmunoassay (Linco, St. Charles, MO, USA)(ESM Box 1). Serum cortisol was 
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measured by a competitive chemiluminescent immunoassay previously validated in cats 
(Bayer, Tarrytown, NY, USA)[29]. 
The acute-phase proteins of inflammation α1-acid glycoprotein and serum amyloid A were 
measured in plasma by a feline-specific radial immunodiffusion test and an ELISA (Tridelta, 
Bray, Ireland). 
 
Assessment of beta-cell function 
During the 10-day infusion period in Group I-III overnight fasting blood samples were 
collected through the jugular catheter daily at 8:00 am to measure glucose and insulin levels. 
An intravenous glucose tolerance test (ivGTT) was performed under anaesthesia in Group I-
III 1 h after the 10-day infusion. Group IV was also admitted to the ivGTT. A glucose bolus 
of 1 g/kg was administered via the jugular catheter. Glucose and insulin concentrations were 
measured before the bolus and from 5 to 120 min thereafter. To estimate beta-cell function the 
insulin secretion index was calculated (ESM Box 2)[30]. After the ivGTT, cats were 
euthanized and the pancreas was excised. 
 
Insulin content of the pancreas 
Pancreatic insulin content was measured in a tissue specimen from the left lobe of the organ 
and 24 h after homogenized in 0.18N HCl in 70% ethanol. Results were normalized to the 
sample’s protein content measured with a spectrophotometer (ND-1000, NanoDrop, 
Wilmington, DE, USA) at 280 nm. 
 
Islet pathology 
Right and left lobes, and the body of the pancreas were examined. One aliquot each was 
formalin-fixed for 24 h and paraffin-embedded. An additional aliquot collected from the left 
lobe was snap-frozen in liquid nitrogen and stored at −80°C. 
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Paraffin sections were stained with hematoxylin and eosin (H&E) for histomorphometry. To 
detect islet amyloid deposits, additional sections were stained with thioflavine-T and Congo 
red. To detect glycogen stores in islets, frozen tissue sections were stained by periodic acid-
schiff (PAS) with or without diastase digestion (1% α-amylase from Bacillus subtilis, Sigma-
Aldrich, Buchs, Switzerland). A frozen section was stained with Oil-red O to detect islet 
accumulation of lipids. 
Immunohistochemical staining procedures for insulin, amylin, Nkx6.1 (beta-cell transcription 
factor), glucagon, cleaved caspase-3, Ki67, proliferating nuclear antigen (PCNA) and 
myeloperoxidase (for neutrophils) were performed as described in ESM Box 3. 
Insulin-, amylin- and glucagon-positive areas relative to the pancreatic area were calculated 
using ImageJ software (http://rsb.info.nih.gov/ij/) on 15 pictures collected from each cat at 
4×-magnification. Large vessels, ducts and interlobular tissue were excluded from 
measurements. 
The number of beta-cells relative to the pancreatic area was calculated by counting Nkx6.1-
positive nuclei in sections double-stained with insulin and Nkx6.1. Twenty pictures were 
collected from each cat at 10×-magnification using Image J. 
The number of islet apoptotic cells and of cleaved caspase-3-positive beta-cells was 
calculated in 5.000 cells. The number of Ki67- or PCNA-positive beta-cells, and the number 
of islet myeloperoxidase-immunostained neutrophils was also calculated in 5.000 cells. 
Counts were not performed in small islets with the longer axis below 50 µm. In addition, 
neutrophils were counted in the exocrine pancreas in 50 microscopic fields at 40×-
magnification, excluding those in large vessels. 
 
Isolation of islets, RNA isolation, reverse transcription and quantitative analysis of mRNA 
Isolation of islets was performed as previously described [31]. Total RNA from islets was 
extracted using the RNeasy Mini Kit (Qiagen, Basel, Switzerland). Genomic DNA 
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contamination was eliminated by including DNase-treatments (DNase-Free DNase Set, 
Qiagen). RNA quality was assessed by gel electrophoresis. cDNA was obtained from 1 µg 
samples of RNA (Omniscript RT-Kit, Qiagen) in the presence of 13U of RNasin (Promega, 
Madison, WI, USA). 
Islet cDNA was subjected to quantitative real-time PCR using feline-specific oligonucleotides 
we established for insulin, Fas receptor, the caspase-8 inhibitor FLIP (FLICE/caspase-8-
inhibitory protein), the chemokines IL-8 and monocyte chemoattractant protein-1 (MCP-1) 
and the housekeeping gene cyclophilin A (ESM Table 2)[31]. Published sets of primers and 
probes for feline IL-6, IL-1β, TNF-α, and the control gene glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were also used (ESM Table 2)[32]. 
For SYBR-Green and probe-based assays, PCR reactions were performed as previously 
described [31]. cDNA samples were run in triplicate and transcripts were quantified using the 
relative standard curve method. Gene expression was normalised to the respective quantities 
of cyclophilin A and GAPDH. 
 
Statistical analysis 
Data are expressed as mean ± SE throughout the text. Data were analyzed using GraphPad 
Prism 4.0 (GraphPad, San Diego, CA, USA). Results were compared with the Mann-Whitney 
or Kruskal-Wallis and Dunn’s tests. Significance was set at P<0.05. Pathology slides were 
evaluated in a blinded manner by two investigators (E.Z., A.P. or R.S.H.). 
 11
Results 
Ten-day hyperglycaemic and hyperlipidaemic clamps are feasible and well tolerated in cats 
The first cat designed to receive glucose was used as a pilot. Glucose was well targeted 
between 25-30 mmol/l from the third day of infusion (ESM Fig 1). The cat tolerated glucose 
infusion without obvious discomfort. This cat was not included in the following analyses. 
In the remaining 5 glucose-infused cats, the expected glucose range was reached within 3-5 h 
after infusion onset. Blood glucose levels were maintained at 25-30 mmol/l for 10 consecutive 
days (Fig 1a). Food intake appeared unaltered and, based on daily physical examinations and 
electrolyte monitoring, the cats were considered in good health (data not shown). With urine 
dipstick (Combur10-Test, Roche) severe glucosuria (4+) was observed from the first day on. 
Ketonuria was never detected. At the end of infusion plasma β-hydroxybutyrate levels were 
not different between glucose-infused cats, cats receiving saline or animals that were not 
infused (glucose: 179 ± 46 µl/l; saline: 180 ± 32 µl/l; no infusion: 157 ± 23 µl/l). Mean body 
weight (BWm) was unchanged from baseline after 10 days of glucose infusion (BWm day 0: 
4.14 kg; BWm day 10: 4.10 kg; BWm difference:1.0%)(Fig 1b). 
Triacylglycerols were targeted at 3-7 mmol/l for most of the infusion period in lipid-infused 
cats (Fig 1c). During the first 2 days, hyperlipidaemia was difficult to target in 3 cats and 
triacylglycerols levels transiently reached 23-45 mmol/l. During that time, two of them 
showed lethargy that rapidly resolved after lipid infusion rate reduction. The NEFA area 
under the curve calculated above zero was significantly higher in lipid- than in saline- 
(P<0.05) or glucose-infused cats (P<0.01)(Fig 1d). In some cats, however, NEFA levels 
varied during infusion. In all lipid-infused cats, food intake, physical examination and 
electrolytes were normal throughout infusion. Lipaemic plasma prevented quantification of β-
hydroxybutyrate. Body weight significantly increased after 10 days of infusion in all lipid-
infused cats (BWm day 0: 3.92 kg; BWm day 10: 4.33 kg; BWm difference: 10.7%; 
P<0.05)(Fig 1b). 
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In saline-infused cats, food intake, physical examination and electrolytes were normal. Body 
weight decreased slightly during infusion (BWm day 0: 4.18 kg; BWm day 10: 4.00 kg; BWm 
difference: 4.3%)(Fig 1b). 
As an indicator of stress, plasma cortisol was measured in cats from Group I-III at the end of 
the infusion period. Cortisol levels were not different between glucose-, lipid- or saline-
infused cats (glucose: 71.7 ± 5.5 nmol/l; lipids: 66.2 ± 16.6 nmol/l; saline: 121.4 ± 22.1 
nmol/l). 
Cats in Group IV (no infusion) had significantly lower cortisol concentrations than saline-
infused cats (27.6 ± 13.8 nmol/l; P<0.05). 
 
Beta-cell function is severely impaired by 10-day glucose but not lipid infusion 
On day 1, glucose-infused cats had a 10-fold increase in the morning plasma insulin levels 
compared to baseline. On day 2 insulin levels markedly declined and remained stable until 
day 4. Thereafter, despite prevailing hyperglycaemia of 25-30 mmol/l, morning insulin levels 
dropped further to reach concentrations close to the detection limit of the assay by day 10 (Fig 
2a). 
In cats on triacylglycerol infusion blood glucose was slightly elevated from day 4 to 10 
compared to saline-infused cats (Fig 1a). Hyperlipidaemic cats had insulin concentrations 
similar to cats on saline throughout the infusion period except for day 1-2, where one single 
cat transiently had higher levels (Fig 2a). This cat concurrently had two of the above 
mentioned episodes of severe hyperlipidaemia. 
One hour after the end of the infusion period an ivGTT was performed. Glucose-infused cats 
had no stimulation of insulin secretion. Lipid-infused cats had a glucose-induced secretory 
response that was similar to controls (Fig 2b). The insulin secretion index was significantly 
lower in glucose- than in saline- (P<0.05) and lipid-infused cats (P<0.05) but did not differ 
between the other groups (Fig 2c). 
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The insulin-positive area in the pancreas is markedly decreased after 10-day glucose but not 
lipid infusion 
In glucose-infused cats, morphometric analysis of sections immunostained for insulin showed 
a severe reduction of the insulin-positive area relative to the pancreatic area. On average, the 
insulin-positive area was 80% smaller in glucose- than in saline-infused cats (Fig 3a,b). Lipid-
infused and saline-infused cats had similar insulin-positive areas. Differences were not 
observed between control groups. 
In glucose-infused cats insulin immunostaining was condensed at the periphery, and in beta-
cells lined by capillaries it was often selectively located towards the cytoplasmic membrane 
adjacent to endothelial cells. In the other groups insulin was homogeneously distributed 
throughout the beta-cell cytoplasm (Fig 3c). 
The insulin content of pancreatic specimens was reduced in four of the five glucose-infused 
cats (Fig 3d). 
The amylin- and glucagon-positive areas relative to the pancreatic area were not different 
between groups (data not shown). However, with regards to the amylin-positive area, we 
detected a relative large variation of up to 200% (3-fold difference) in cats infused with saline 
or that did not receive infusion. This variation may be a confounding factor to reliably detect 
differences in the amylin-positive area between groups. Similar to insulin immunostained 
sections, amylin immunostaining in glucose-infused cats was unevenly distributed in the 
cytoplasm of several beta-cells. To exclude the possibility that deposits of amylin-derived 
amyloid were included in the measurement of the amylin-positive area by anti-amylin 
antibodies, sections were stained with thioflavine-T and Congo red. Amyloid deposits were 
not detected with either staining method in any cat. 
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Severe loss of beta-cells occurs after 10-day glucose but not lipid infusion 
The number of beta-cells was estimated by counting the number of beta-cell nuclei stained 
with Nkx6.1 relative to the pancreatic area. Compared to the number of beta-cells found in 
saline- or lipid-infused cats, the number of beta-cells in glucose-infused cats was reduced by 
about half (P<0.05)(Fig 4a,b). 
The decreased number of islet cells in glucose-infused cats was evident when islet cell nuclei 
were evaluated on H&E stained sections. In this group the majority of islet cells appeared to 
contain clear cytoplasm and considerable areas of the islets appeared devoid of nuclei (Fig 
4c). 
 
Apoptosis contributes to beta-cell loss in glucose-infused cats 
We detected apoptotic islet cells in glucose-infused cats only. Based on morphologic criteria, 
four of the five glucose-infused cats had islet cells with nuclei showing typical pycnosis or 
karyorrhexis (Fig 5a,b). Islet cells with these apoptotic features were not observed in any 
other cat. Using immunostaining for cleaved caspase-3, three of the four glucose-infused cats 
with pycnosis or karyorrhexis had positive beta-cells (Fig 5c). 
The number of proliferating beta-cells as assessed by insulin and Ki67 or PCNA 
immunostaining was not different between groups (Fig 5d,e). 
 
Glucose infusion induces beta-cell accumulation of glycogen 
To investigate the nature of the clear cytoplasm identified in the islets of glucose-infused cats 
(Fig 4c), staining for glycogen and lipids were performed. Pre-digestion of glycogen with 
diastase followed by PAS staining suggested that islets of glucose-infused cats accumulated 
glycogen (Fig 6). Based on Oil-red O staining, triacylglycerols were not stored in islets of 
glucose-, lipid- or saline-infused cats. 
 
 15
Insulin mRNA expression is downregulated after 10-day glucose but not lipid infusion 
The average expression of insulin mRNA was approximately four-fold lower in isolated islets 
of glucose- than of saline-infused cats (P<0.05)(Fig 7). No difference was observed between 
lipid- and saline-infused cats. The amount of insulin mRNA was higher in saline-infused cats 
than in cats that did not receive any infusion (P<0.05). Comparable results were achieved 
when insulin transcripts were normalized with GAPDH or cyclophilin A (data not shown). 
The mRNA quantities of Fas receptor and FLIP were similar between groups (data not 
shown). 
 
Glucose and lipid infusion induce a systemic inflammatory reaction 
After 10 days of infusion, circulating levels of α1-acid glycoprotein, but not serum amyloid A, 
were significantly increased in glucose- and lipid-infused cats compared to saline-infused cats 
(P<0.05). Plasma concentrations did not differ between the two control groups (ESM Fig 2a). 
The mRNA levels of cytokines and chemokines, including IL-6, IL-1β, TNF-α, IL-8 and 
MCP-1, as assessed in isolated islets did not differ between groups (data not shown). 
Glucose- or lipid-infused cats had similar islet neutrophil numbers as saline-infused cats 
(myeloperoxidase immunostaining)(ESM Fig 2b,c). However, glucose-infused cats had 
significantly higher counts compared with lipid-infused cats (P<0.05). Furthermore, glucose-
infused cats showed a trend towards an increased neutrophil number in the exocrine pancreas, 
as compared to the other groups (ESM Fig 2d). Neutrophil counts in islets or exocrine 
pancreas were not different between control groups. 
Macrophages were not counted in cat islets due to the lack of cross-reacting antibodies (ESM 
Table 3). 
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Discussion 
Using long-term hyperglycaemic and hyperlipidaemic clamps in cats, we developed an animal 
model suitable to study the pathogenesis of beta-cell dysfunction and loss induced by excess 
glucose or lipids in vivo. Plasma glucose and lipid levels were successfully targeted for 10 
days in the range seen in cats with untreated diabetes [27,28]. Glucose-infused cats were non-
ketotic and hyperlipidaemia increased the area under the curve for NEFA. Based on physical 
examination, food intake, body weight and electrolyte monitoring, hyperglycaemia and 
hyperlipidaemia were well tolerated in cats. Cage rest and chronic intravenous infusion 
increased basal cortisol levels compared to cats without infusion, suggesting that the 
experimental set-up induced a slight stress response. However, cortisol concentrations were 
not different between groups infused with glucose, lipids or saline. 
Different from previous rodent models where glucose was infused for 2-4 days [9-14], our 
experiment shows that severe beta-cell dysfunction is rapidly induced by sustained 
hyperglycaemia in cats. Plasma insulin levels markedly declined by the second day of glucose 
infusion and were below baseline by day 10. After infusion, an acute glucose bolus did not 
stimulate insulin secretion as addressed in the ivGTT. In addition, most hyperglycaemic cats 
had lower pancreatic insulin contents than saline-infused cats. Pancreatic sections of 
hyperglycaemic cats had insulin-positive areas reduced by 80%. This finding is probably due 
to depletion of insulin stores in this group. Furthermore, the decrease of insulin gene 
transcription observed in hyperglycaemic cats showed that chronic over-stimulation of beta-
cells with glucose caused a reduction in insulin synthesis. To support this notion we found 
that in those cats insulin was distributed as a thin rim at the beta-cell periphery. Because pro-
insulin is concentrated in the Golgi apparatus of normal beta-cells [33], the lack of perinuclear 
immunostaining may suggest that early steps in the process of insulin synthesis were 
disturbed. Collectively these findings demonstrate that sustained hyperglycaemia strongly 
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impairs beta-cell function in cats, and that this is due to beta-cell exhaustion and decreased 
insulin gene expression. 
This study supports the hypothesis that hyperglycaemia itself causes beta-cell loss in vivo, as 
indicated by the 50% decrease in the number of beta-cells per pancreatic area found in 
glucose-infused cats, which was not compensated by increased beta-cell proliferation. Based 
on histomorphological features, hyperglycaemic cats had large parts of most islets devoid of 
nuclei. In most rodent studies, glucose infusion for 2-4 days either increased or had no effect 
on beta-cell mass [12,14,15-17]. None of these in vivo experiments demonstrated a demise of 
beta-cells after infusion. As to the reason for the reduced number of beta-cells in 
hyperglycaemic cats, we found that apoptotic islet cells and beta-cells positive for cleaved 
caspase-3 were only present in glucose-infused cats. Apoptosis may thus contribute to the 
reduced number of beta-cells in hyperglycaemic cats. This is consistent with in vitro studies 
that have shown that high glucose levels increase the rate of beta-cell apoptosis in human 
islets or in islets of the Psammomys obesus [4,5,34]. 
In the islets isolated from hyperglycaemic cats we found no increase in IL-1β or the Fas 
receptor. Hence, differently from human islets exposed to high glucose levels [4,5], apoptosis 
of beta-cells in hyperglycaemic cats may have occurred through mechanisms not involving a 
local inflammatory reaction or Fas receptor up-regulation. Of note, we observed that 
substantial amounts of glycogen had accumulated in the islets of hyperglycaemic cats. 
Deposits of glycogen have been described in the islets of diabetic humans and animals [35-
37] and have been proposed to account, at least in part, for the beta-cell secretory defect 
induced by excess glucose [38]. Whether glycogen accumulation also contributes to beta-cell 
loss has not been studied. Recently, it has been shown that beta-cell overexpression of 
glycogen synthase kinase-3 is associated with beta-cell dysfunction and loss in rats [39]. 
Interestingly, this enzyme is both linked to glycogen synthesis and to proliferation/apoptosis. 
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The link between glycogen metabolism and cell survival makes this gene a possible candidate 
to explain beta-cell apoptosis in the present investigation. 
We show that feline beta-cells are very susceptible to the effects of marked hyperglycaemia. It 
is however worth noting that part of the observed toxic changes may have been induced by 
the fast increase of glucose levels in the islet milieu rather than by the sustained 
hyperglycaemia. To better mimic the natural history of feline diabetes a gradual ramp-up of 
glucose levels would have required infusion over several weeks. Such a gradual increase of 
hyperglycaemia was not performed because long-term infusion may increase the risk of 
septicaemia and is critical for animal welfare reasons. Clamps could also have been 
performed at lower blood glucose levels to provide information upon the mechanisms 
involved in earlier phases of beta-cell failure. However, to study the principal mechanisms of 
hyperglycaemic-induced beta-cell damage, we decided to target hyperglycaemia at levels seen 
in untreated diabetes. 
In contrast to the detrimental effects of hyperglycaemia, hyperlipidaemia leading to increased 
plasma levels of NEFA did not affect basal insulin or glucose-induced insulin secretion in the 
ivGTT. Similar insulin mRNA quantities between hyperlipidaemic and saline-infused cats 
may suggest that insulin gene transcription was not affected by lipid infusion. Conflicting 
results have been described with regard to the effects of excess NEFA on insulin secretion in 
vivo. Studies in rats and humans reported increased, decreased or unchanged beta-cell 
function [18,19,40,41]. Such differences may partly be attributable to the various protocols of 
infusion. Here, to mimic the in vivo milieu of diabetic cats we targeted triacylglycerols at the 
concentration found in feline diabetes [27,28]. This led to a 1.7 fold-increase of plasma 
NEFA, hence similar to the 2-fold increase of NEFA concentrations in untreated diabetic 
versus healthy cats (unpublished observation). 
Hyperlipidaemia and excess NEFA levels in cats had no effect on the number of beta-cells 
and rate of beta-cells undergoing apoptosis or proliferation. In cultured human and rat islets, 
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exposure of beta-cells to palmitate appears toxic, whereas oleate protects from both palmitic- 
and glucose-induced beta-cell apopotosis [7,8]. Because the emulsion used to induce 
hyperlipidaemia in our cats contained approximately 3-fold higher amounts of oleate than 
palmitate, it is possible that the protective effect of oleate outweighed the negative effect of 
palmitate. Accumulation of lipids and, possibly, of toxic lipid by-products was not observed 
in beta-cells. Thus, the present work reveals that feline beta-cells in vivo are resistant to 10 
days of hyperlipidaemia and excess NEFA. 
It is important to note that in the present study the degree of hyperlipidaemia, particularly of 
NEFA, was proportionally lower than the degree of hyperglycaemia, thus making direct 
comparison of the two infusion regimens difficult. In addition, during infusion NEFA levels 
varied widely in some cats. Therefore, it is possible that substantial beta-cell damage would 
have occurred in cats if lipids were clamped at higher concentrations and NEFA levels were 
constantly increased. Further, it has to be kept in mind that the concept of beta-cell 
lipotoxicity is often considered relevant only when coupled with glucotoxicity [1]. Future 
studies will have to show whether concurrent infusion of glucose and lipids have a combined 
effect on the beta-cells in vivo. 
We found that both hyperglycaemia and hyperlipidaemia induced systemic inflammation in 
cats, as shown by an increased plasma concentration of α1-acid glycoprotein, the most 
important feline acute phase protein [42]. Hence, systemic inflammation may develop in cats 
exposed to a diabetic milieu similar to what has been described in human type 2 diabetes [43]. 
Differently from observations in type 2 diabetic humans [44], we did not observe an 
inflammatory reaction in islets of hyperglycaemic or hyperlipidaemic cats, as assessed by islet 
transcript quantities of cytokines or chemokines and by the number of islet neutrophils. The 
reason for a higher neutrophil number in the islets and exocrine pancreas of glucose- as 
compared to lipid-infused cats remains unclear. 
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In conclusion, clamping plasma glucose and lipid levels is feasible in cats, and the in vivo 
model is appropriate to study the pathogenesis of beta-cell dysfunction and beta-cell demise 
that may occur in poorly controlled diabetes. Ten days of hyperglycaemia severely impaired 
beta-cell secretory capacity and caused marked beta-cell loss in cats. Apoptosis may 
contribute to beta-cell demise. Hyperlipidaemia, despite increasing NEFA levels, did not 
induce beta-cell dysfunction and loss in cats. 
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Figure legends 
 
Fig 1. (a) Blood glucose levels during the 10-day infusion period in glucose- (black 
rhombus), lipid- (white triangle) and saline-infused (black triangle) cats. Hyperglycaemia in 
glucose-infused cats was well targeted at 25-30 mmol/l. Blood glucose levels slightly 
increased in lipid-infused cats between day 5 and 10 (average increase above baseline: 0.7 
mmol/l), but remained within the limits reported for healthy cats (Clinical Laboratory of the 
Vetsuisse Faculty, University of Zuerich; reference range: 3-8 mmol/l). Values are expressed 
as mean ± SE. (b) Body weight of saline-, glucose- or lipid-infused cats before (Pre) and after 
(Post) infusion. After infusion, body weight decreased slightly in saline-infused cats (average 
difference: 4.3%), was stable in glucose-infused cats (average difference: 1.0%) and 
significantly increased in lipid-infused cats (average difference: 10.7%; P<0.05). Individual 
values are shown. (c) Triacylglycerol levels during the 10-day infusion period in glucose- 
(black rhombus), lipid- (white triangle) and saline-infused (black triangle) cats. In lipid-
infused cats hyperlipidaemia was maintained over 10 days of infusion. Plasma triacylglycerol 
levels were adequately targeted at 3-7 mmol/l, in particular between day 3 and 10. Values are 
expressed as mean ± SE. (d) Circulating NEFA were measured eight times (from day 2 to 9) 
during the infusion period in each glucose- (black rhombus), lipid- (white triangle) and saline-
infused (black triangle) cat. Values are expressed as mean ± SE. The calculated area under the 
curve for NEFA was higher in lipid- than in saline- (P<0.05) or glucose-infused cats 
(P<0.01).  
 
Fig 2. (a) Plasma insulin levels during the 10-day period of glucose, lipids and saline infusion 
in cats. In glucose-infused cats (black rhombus) insulin concentrations markedly increased 
during the first 24 h and progressively decreased thereafter. In lipid-infused cats (white 
triangle) insulin concentrations did not differ from those in saline-infused cats (black 
 27
triangle). Values are expressed as mean ± SE. (b) Insulin levels during the ivGTT performed 
one hour after the 10-day period of infusion. Insulin levels did not increase in glucose-infused 
cats (black rhombus) whereas lipid- (white triangle) and saline-infused cats (black triangle) 
and cats without infusion (black square) had a similar insulin response. Values are expressed 
as mean ± SE. (c) Insulin secretion index derived from the ivGTT (formula in Appendix 3). 
The insulin secretory index was significantly lower in glucose-infused cats than in cats 
infused with saline (P<0.05) or lipids (P<0.05). Values are expressed relative to one cat 
without infusion; individual values and means are shown. 
 
Fig 3. (a) Insulin immunostaining (pink) of feline pancreatic islets. Large image shows 
overview of a pancreatic section. Squares designate region shown at higher magnification 
(insert). (b) The insulin-positive area was significantly smaller in glucose-infused than in cats 
infused with saline (P<0.05) or lipids (P<0.05). The insulin-positive area did not differ 
between the two control groups. Insulin-positive area was calculated as a percentage of the 
total pancreatic area and values are expressed relative to one cat without infusion; individual 
values and means are shown. (c) Pancreatic islet of a glucose-infused cat. In the beta-cells of 
glucose-infused cats, insulin immunostaining (pink) was mainly localized at the cell 
periphery. In the same cats, insulin immunostaining in beta-cells lined by capillaries was 
often shifted towards the cytoplasmic membrane adjacent to endothelial cells (arrowheads). 
(d) Insulin content of the pancreas. In four glucose-infused cats the insulin content of 
pancreatic specimens was lower than in saline-infused cats. Insulin levels were normalized to 
the protein content measured with a spectrophotometer (optic density: 280 nm) and values are 
expressed relative to one cat without infusion; individual values and means are shown. 
 
Fig 4. (a) Number of beta-cells relative to the pancreatic area. Nkx6.1-positive cells were 
counted in pancreatic sections double stained with Nkx6.1 and insulin. The number of beta-
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cells was reduced by approximately half in glucose-infused cats compared with saline- 
(P<0.05) or lipid-infused cats (P<0.05). (b) Nkx6.1 (black) and insulin (brown) 
immunostaining of pancreatic islets in cats (40×). Few Nkx6.1-positive nuclei are observed in 
the islet of the glucose-infused cat. In the same cat insulin staining is decreased. Values are 
expressed relative to one cat without infusion; individual values and means are shown. (c) 
H&E staining of pancreatic islets in cats (40×). In the glucose-infused cat a large area on the 
left side of the islet appears devoid of nuclei and includes several vacuoles. 
 
Fig 5. (a) Numbers of islet apoptotic cells. Glucose-infused cats had significantly more islet 
apoptotic cells than cats infused with saline (P<0.05) or lipids (P<0.05). Individual values and 
means are shown. (b) H&E staining of three pancreatic islets of glucose-infused cats (40×). 
Arrows show nuclei with morphologic features of apoptosis. (c) Triple immunostaining for 
insulin (green), Nkx6.1 (blue) and cleaved caspase-3 (red) of pancreatic islets in cats (40×). 
An apoptotic beta-cell positive for cleaved caspase-3 is identified in the islet of a glucose-
infused cat (arrow). (d) Numbers of proliferating beta-cells. The number of proliferating cells 
was not different between groups. In two of the glucose-infused cats several proliferating 
beta-cells were observed. Individual values and means are shown. (e) Triple immunostaining 
for insulin (green), Nkx6.1 (red) and Ki67 (blue) of pancreatic islets in cats (40×). A 
proliferating beta-cell is shown in the islet of a glucose-infused cat (arrow). Proliferating cells 
were also observed in the exocrine pancreas adjacent to the islet of the other cats (arrows). 
 
Fig 6. Feline pancreatic sections stained with PAS (40×). A consecutive section of the 
glucose-infused cat was pre-digested with diastase (Diastase)(40×). Islet loss of PAS-
positivity after diastase digestion indicated that glycogen was accumulated in islets of 
glucose-infused cats. 
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Fig 7. Relative quantities of insulin mRNA in isolated islets. Insulin transcripts were four-fold 
lower in glucose- than in saline-infused cats (P<0.05). Cats that did not receive infusion had 
lower insulin expression levels than saline-infused cats (P<0.05). Values are expressed 
relative to one cat without infusion; individual values and means are shown. 
